E-Mail Alert

Add your e-mail address to receive forthcoming issues of this journal:

Journal Browser

Journal Browser

Special Issue "New Agents Targeting Regulators of Protein Homeostasis for Cancer Therapy"

Quicklinks

A special issue of Pharmaceuticals (ISSN 1424-8247).

Deadline for manuscript submissions: closed (30 May 2015)

Special Issue Editor

Guest Editor
Dr. Jennifer S. Carew (Website)

Cleveland Clinic Taussig Cancer Institute, Cleveland Clinic Main Campus, 9500 Euclid Avenue Cleveland, OH 44195, USA

Special Issue Information

Dear Colleagues,

The journal “Pharmaceuticals” is planning to publish a special issue covering the topic “New Agents Targeting Regulators of Protein Homeostasis for Cancer Therapy” and I am cordially inviting you to contribute an article to this volume.

Protein homeostasis is essential for many critical cellular processes, including cell cycle progression, signal transduction, and cell death. The ubiquitin-proteasome system controls the turnover of most short-lived intracellular proteins, while autophagy functions as a mechanism for the bulk degradation of organelles and proteins with long half-lives. Protein turnover frequently becomes dysregulated in cancer and aberrant protein degradation contributes to disease progression, metastasis, and drug resistance. As such, targeting abnormal protein degradation in cancer is an appealing therapeutic strategy. A number of agents that inhibit both ubiquitin-proteasome mediated protein turnover and autophagic degradation are currently under investigation for their potential applications in cancer therapy in preclinical studies and clinical trials. This Special Issue will focus on new developments related to targeting regulators of protein turnover as an anticancer strategy.

Dr. Jennifer S. Carew
Guest Editor

jennifer-photo

Submission

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed Open Access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 800 CHF (Swiss Francs).


Published Papers (1 paper)

View options order results:
result details:
Displaying articles 1-1
Export citation of selected articles as:

Review

Open AccessReview Clinical Use of Proteasome Inhibitors in the Treatment of Multiple Myeloma
Pharmaceuticals 2015, 8(1), 1-20; doi:10.3390/ph8010001
Received: 29 July 2014 / Accepted: 4 December 2014 / Published: 24 December 2014
Cited by 9 | PDF Full-text (719 KB) | HTML Full-text | XML Full-text
Abstract
Multiple myeloma (MM) is an incurable hematological malignancy characterized by the clonal proliferation of neoplastic plasma cells. The use of proteasome inhibitors in the treatment of MM has led to significant improvements in outcomes. This article reviews data on the use of [...] Read more.
Multiple myeloma (MM) is an incurable hematological malignancy characterized by the clonal proliferation of neoplastic plasma cells. The use of proteasome inhibitors in the treatment of MM has led to significant improvements in outcomes. This article reviews data on the use of the two approved proteasome inhibitors (bortezomib and carlfilzomib), as well as newer agents under development. Emphasis is placed on the clinical use of proteasome inhibitors, including management of side effects and combination with other agents. Full article

Journal Contact

MDPI AG
Pharmaceuticals Editorial Office
St. Alban-Anlage 66, 4052 Basel, Switzerland
pharmaceuticals@mdpi.com
Tel. +41 61 683 77 34
Fax: +41 61 302 89 18
Editorial Board
Contact Details Submit to Pharmaceuticals
Back to Top